Evinacumab is highlighted as a new therapy for treating patients with homozygous FH. Eliot Brinton, MD: There has been a recent breakthrough in HoFH [homozygous familial hypercholesterolemia] ...

Discover comprehensive details about Lomitapide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with ...

Homozygous familial hypercholesterolemia is a rare genetic condition that is often characterized by an increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide decreases ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

The APH-19 trial enrolled a total of 46 patients 5 to 17 years of age with HoFH who had a mean LDL-C at baseline of 436 mg/dL. Lomitapide was associated with statistically significant reductions in ...

Ning Yang, Ph.D. and Andrew McDonald, Ph.D. Aegerion's (AEGR) stock has risen roughly 50% since October 11, 2012. We attended the company's investor event in New York on October 23, and it's clear ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

The FDA has approved lomitapide (Aegerion Pharmaceuticals, Cambridge, MA) as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL-C, total ...

London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...

In briefing documents ahead of an advisory committee meeting on October 17, an FDA panel stated, "In considering a risk management program for lomitapide, FDA must keep in mind that the HoFH patient ...